The store will not work correctly when cookies are disabled.
2-isobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione
ID: ALA4760355
PubChem CID: 85090335
Max Phase: Preclinical
Molecular Formula: C22H21N3O2
Molecular Weight: 359.43
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: CC(C)Cc1nc2c(c(=O)c3ccccc3n2C)c(=O)n1-c1ccccc1
Standard InChI: InChI=1S/C22H21N3O2/c1-14(2)13-18-23-21-19(22(27)25(18)15-9-5-4-6-10-15)20(26)16-11-7-8-12-17(16)24(21)3/h4-12,14H,13H2,1-3H3
Standard InChI Key: BOHIDHFZQOGFHD-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 30 0 0 0 0 0 0 0 0999 V2000
19.2925 -9.2574 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.2913 -10.0847 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0061 -10.4975 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0043 -8.8447 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.7196 -9.2538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.7204 -10.0805 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.4356 -10.4914 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
21.4300 -8.8396 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.1458 -9.2468 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.1494 -10.0764 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.8684 -10.4861 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.5843 -10.0676 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.5768 -9.2349 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.8571 -8.8289 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.4256 -8.0148 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
22.8500 -8.0040 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
24.2819 -8.8167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.0005 -9.2241 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7105 -8.8056 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7030 -7.9798 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.9797 -7.5744 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.2727 -7.9952 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.2972 -10.4739 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.3013 -11.2998 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.0145 -11.7070 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.5889 -11.7158 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.4378 -11.3163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 10 1 0
9 8 1 0
8 5 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 13 1 0
13 14 1 0
14 9 1 0
8 15 2 0
14 16 2 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 17 1 0
13 17 1 0
23 24 1 0
24 25 1 0
12 23 1 0
24 26 1 0
7 27 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 359.43 | Molecular Weight (Monoisotopic): 359.1634 | AlogP: 3.44 | #Rotatable Bonds: 3 |
Polar Surface Area: 56.89 | Molecular Species: NEUTRAL | HBA: 5 | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: ┄ | CX LogP: 4.23 | CX LogD: 4.23 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.53 | Np Likeness Score: -0.83 |
References
1. Luderman KD,Jain P,Benjamin Free R,Conroy JL,Aubé J,Sibley DR,Frankowski KJ. (2021) Development of pyrimidone D1 dopamine receptor positive allosteric modulators., 31 [PMID:33221389] [10.1016/j.bmcl.2020.127696] |